Genmab — Januar 2022
-
-
Clinical development of candidate vaccines for S. aureus, C. difficile, P. aeruginosa, ExPEC and N. gonorrhoeae has so far failed....Compared with a few years ago, we now have a much better understanding of the contribution of functional antibodies, cell-mediated immunity and innate immunity in mediating protection against these pathogens
-
-
God morgen.
-
God morgen.
-
Godmorgen. Tak for bidraget @HHM - tillader mig, at linke til support siden for Proinvestor.com, hvor man også kan bidrage
https://www.proinvestor.com/donation -
Tak. Kan anbefale chatgruppen for "aktiesnakken" eller "debat-området", hvor der kan føres mere generelle indlæg, som ikke nødvendigvis rammer Genmab chatten spot on
-
Aktier/åbning: C25 helt i grønt - forsikringsselskaber slipper billigt
https://www.proinvestor.com/investornyt/773502/aktier-abning-c25-helt-i-gront-forsikringsselskaber-slipper-billigt -
Aktier/middag: C25-rutsjebaneturen fortsætter med biotek i topform
https://www.proinvestor.com/investornyt/773530/aktier-middag-c25-rutsjebaneturen-fortsaetter-med-biotek-i-topform -
Genmab/HC Wainwright: ADR-notering hæves til "køb" fra "neutral"
https://www.proinvestor.com/investornyt/773555/genmab-hc-wainwright-adr-notering-haeves-til-kob-fra-neutral
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind